Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4I3HU
|
|||
| Drug Name |
Obexelimab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | IgG4 related disease [ICD-11: 4A43.0; ICD-10: M35, M35.8] | Phase 3 | [1] | |
| Company |
Xencor Monrovia, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-lymphocyte surface antigen B4 (CD19) | Target Info | . | [2] |
| KEGG Pathway | PI3K-Akt signaling pathway | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Epstein-Barr virus infection | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | IL-7 Signaling Pathway | |||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | PIP3 activates AKT signaling | |||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | Human Complement System | |||
| Signaling by the B Cell Receptor (BCR) | ||||
| PIP3 activates AKT signaling | ||||
| B Cell Receptor Signaling Pathway | ||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05662241) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO). U.S.National Institutes of Health. | |||
| REF 2 | Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.